Patients with cryptogenic stroke often face difficult choices about blood thinners. This research matters because it compares two common options: apixaban and aspirin. The goal was to see how these drugs affect bleeding risks in people who have had a stroke without a clear cause but show signs of atrial cardiopathy. Understanding these risks helps doctors and patients weigh the benefits of preventing clots against the dangers of bleeding.
Researchers conducted a randomized trial involving 1,015 patients across multiple centers. Participants were assigned to take either apixaban or aspirin. The study tracked them for a mean of 1.8 years, with a standard deviation of 1.2 years. The primary focus was on hemorrhage, or bleeding, events. Secondary outcomes included specific types of bleeding such as intracranial hemorrhage, which occurs inside the skull, and major non-intracranial hemorrhage, which occurs outside the skull.
The results showed that 115 out of 1,015 patients experienced 146 hemorrhages overall. When looking specifically at intracranial hemorrhage, apixaban resulted in significantly fewer events than aspirin. The absolute risk difference was 1.4 percent lower with apixaban. The confidence interval for this difference ranged from 2.3 percent to 0.5 percent. For symptomatic intracranial hemorrhage, the findings were similar, showing a risk reduction of 1.1 percent. However, for major non-intracranial hemorrhage and any major hemorrhage, the risks did not differ significantly between the two drugs. Minor hemorrhage risks also showed no significant difference.
Safety concerns centered on the various types of hemorrhages. The study classified adverse events into intracranial, symptomatic intracranial, major non-intracranial, and any major and minor hemorrhages. Patients who permanently stopped taking the study drug were censored in the safety sample. The study did not report serious adverse events separately or data on tolerability. No specific funding or conflicts of interest were reported in the available information.
It is important to note that this is a single randomized trial. While the design allows for strong comparisons, one study cannot change practice on its own. The evidence is limited by the sample size and the specific population studied. People should not overreact to these findings as they apply only to patients with cryptogenic stroke and evidence of atrial cardiopathy. This study does not prove that apixaban is better for everyone, only for this specific group in this specific trial.
For patients right now, this research adds to the conversation about blood thinner choices. It suggests that apixaban may offer a lower risk of intracranial bleeding compared to aspirin for this specific condition. However, doctors must consider all factors, including individual patient history and other risks. This study provides data but does not replace clinical judgment. Patients should discuss these options with their healthcare providers to make informed decisions about their care.